Citigroup Maintains 'Buy' Rating for Zymeworks Inc. (NASDAQ: ZYME) Following Strategic Acquisition

• Citigroup's Positive Outlook: Citigroup (NYSE: C) maintains a "Buy" rating for Zymeworks Inc. (NASDAQ: ZYME) at a stock price of $27.12, driven by recent strategic developments.
• Transformative Acquisition: Zymeworks' acquisition of Theravance Biopharma (NASDAQ: TBPH) aims to diversify cash flows and integrate research and development with revenue-generating assets.
• Strong Financial Projections: The acquisition, including the product YUPELRI, is expected to be accretive, leading to updated 2026 guidance of $278 million - $292 million in total revenue and $114 million - $128 million in Adjusted EBITDA.

Citigroup (NYSE: C) maintains its "Buy" rating for Zymeworks Inc. (NASDAQ: ZYME), a leading biotechnology company focused on developing innovative new therapies. The investment rating was affirmed on September 29, 2026, when the stock price was $27.12. This positive outlook follows significant strategic developments within the company, including a major acquisition that is set to reshape its financial future.

A key driver for this favorable rating is Zymeworks' recent corporate acquisition of Theravance Biopharma (NASDAQ: TBPH), as highlighted by Seeking Alpha. This strategic move aims to transform the biotechnology firm by diversifying its cash flows. The overarching goal is to seamlessly integrate its research and development capabilities with a growing portfolio of pharmaceutical assets that generate sustainable revenue and royalties.

A pivotal component of this acquisition is the product YUPELRI, which is anticipated to provide immediate revenue and cash flow. This transaction is considered "accretive," meaning it is projected to increase Zymeworks' earnings per share (EPS). The company intends to retain the existing commercial team, leveraging their expertise in promoting the product within hospital networks.

Reflecting the integration of this new asset, Zymeworks has updated its 2026 financial guidance. The biotechnology innovator now projects total revenue to be between $278 million and $292 million. Furthermore, Adjusted EBITDA, a key measure of operating profitability before certain non-cash expenses, is expected to range from $114 million and $128 million for the fiscal year.